The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less.
A. M. Gonzalez-Angulo
No relevant relationships to disclose
W. E. Barlow
No relevant relationships to disclose
J. Gralow
Research Funding - Amgen; Genentech; Novartis; Roche
F. Meric-Bernstam
No relevant relationships to disclose
D. F. Hayes
No relevant relationships to disclose
C. Moinpour
No relevant relationships to disclose
S. D. Ramsey
No relevant relationships to disclose
A. F. Schott
No relevant relationships to disclose
D. B. Sparks
No relevant relationships to disclose
K. S. Albain
Consultant or Advisory Role - Genomic Health
Honoraria - Genomic Health
G. N. Hortobagyi
No relevant relationships to disclose